Ratings by BTIG (Amanda Murphy)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/5/2022 | Adeptus Biotechnologies Corp. | ADPT | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2022 | Adeptus Biotechnologies Corp. | ADPT | Maintain | Buy (N/A) |
|
Details | ||
| 2/16/2022 | Adeptus Biotechnologies Corp. | ADPT | Maintain | Buy (N/A) |
|
Details | ||
| 11/4/2021 | Adeptus Biotechnologies Corp. | ADPT | Maintain | Buy (N/A) |
|
Details | ||
| 5/6/2021 | Adeptus Biotechnologies Corp. | ADPT | Maintain | Buy (N/A) |
|
Details | ||
| 1/19/2021 | Adeptus Biotechnologies Corp. | ADPT | Maintain | Buy (N/A) |
|
Details | ||
| 4/2/2020 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2020 | Cellular Biomedicine Group | CBMG | Downgrade | Neutral (Buy) |
769.76 (19.75) |
-97.43% | Details | |
| 3/5/2020 | Cellular Biomedicine Group | CBMG | Downgrade | Neutral (Buy) |
16.78 (19.75) |
17.7% | Details | |
| 3/3/2020 | Fate Therapeutics | FATE | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2020 | Cerus | CERS | New Coverage | Buy (N/A) |
5.03 (1.93) |
-61.63% | Details | |
| 2/19/2020 | Cellectis | CLLS | Maintain | Buy (N/A) |
|
Details | ||
| 12/6/2019 | Magenta Therapeutics | MGTA | New Coverage | Buy (N/A) |
12.98 (11.58) |
-10.79% | Details | |
| 9/17/2019 | Cellular Biomedicine Group | CBMG | New Coverage | Buy (N/A) |
14.78 (16.78) |
13.53% | Details | |
| 8/15/2019 | Precision BioSciences Inc. | DTIL | New Coverage | Buy (N/A) |
9.17 (4.61) |
-49.73% | Details | |
| 8/15/2019 | Fate Therapeutics | FATE | New Coverage | Buy (N/A) |
18.26 (1.33) |
-92.72% | Details | |
| 8/15/2019 | Cellectis | CLLS | New Coverage | Buy (N/A) |
13.21 (3.56) |
-73.05% | Details | |
| 8/15/2019 | Allogene | ALLO | New Coverage | Buy (N/A) |
28.36 (2.30) |
-91.89% | Details | |
| 7/30/2019 | CRISPR Therapeutics | CRSP | Maintain | Buy (N/A) |
|
Details | ||
| 7/23/2019 | Adeptus Biotechnologies Corp. | ADPT | New Coverage | Buy (N/A) |
38.53 (14.86) |
-61.43% | Details | |
| 2/8/2019 | Intellia Therapeutics | NTLA | New Coverage | Buy (N/A) |
13.86 (13.44) |
-3.03% | Details | |
| 2/8/2019 | Editas Medicine | EDIT | New Coverage | Buy (N/A) |
21.10 (2.00) |
-90.52% | Details | |
| 2/8/2019 | CRISPR Therapeutics | CRSP | New Coverage | Buy (N/A) |
32.63 (56.50) |
73.15% | Details |
